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Abstract
Aims—A recent study found that variation in camptothecin pharmacodynamic genes (TOP1,
PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated
cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes
to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations
using an independent sample of patients receiving irinotecan.
Materials & methods—DNA was isolated from 85 advanced cancer patients treated with 300 or
350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1,
TDP1 and XRCC1. Associations between genotypes and haplotypes and log(absolute neutrophil
count nadirs) were assessed by linear regression.
Results—No associations were observed.
Conclusion—Our findings suggest that the genes we tested do not influence toxicity of irinotecan
when adminstered at 300-350 mg/m2.
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Irinotecan is a semi-synthetic derivative of camptothecin. It is approved for first-line treatment
of metastatic colorectal cancer in combination with 5-fluorouracil/leucovorin and as salvage
therapy in 5-fluorouracil refractory disease in the USA. Results of Phase III trials indicate the
addition of irinotecan to 5-fluorouracil/leucovorin improves rate of response, time to
progression and median survival over 5-fluorouracil/leucovorin alone [1,2]. Irinotecan is also
active when combined with bevacuzimab or cetuximab [3,4]. The dose limiting toxicities of
irinotecan-based therapies include myelosuppression and late-onset diarrhea, the latter of
which can be life threatening if not managed appropriately [5].
The anticancer activity of irinotecan is dependent upon enzymatic conversion by
carboxylesterases to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38).
Detoxification of SN-38 is predominantly via glucuronidation to SN-38-glucuronide (SN-38G)
by hepatic uridine diphosphate-glucuronosyltransferases, principally UGT1A1. Many
pharmacogenetic investigations of irinotecan pharmacokinetics and toxicity have been
conducted [5-7]. The most studied gene to date is UGT1A1, which is located on chromosome
2q37. A common tandem repeat polymorphism in the TATA box of the promoter of the gene
(-53A(TA)nTAA) has been described and an inverse relationship between the number of TA
repeats and the transcriptional activity of the gene has been established [8]. Patients
homozygous for seven TA repeats (UGT1A1*28/*28) have a reduced SN-38 glucuronidation
rate (SN-38G:SN-38 area under the curve ratio), elevated SN-38 area under the curve and an
increased risk of severe toxicity, especially neutropenia, compared with patients heterozygous
or homozygous for six TA repeats (UGT1A1*1/*28 or UGT1A1*1/*1) [9-14]. The association
between UGT1A1*28/*28 genotype and toxicity appears to be dose dependent, with strong
associations observed at doses of more than 250 mg/m2 [15].
Pharmacodynamic genes have not been well studied for irinotecan. Alterations in
topoisomerase I (topo I) activity (TOP1) that result in reduced levels of the SN-38-topo I-DNA
complex and the events downstream from the ternary complex, for example apoptosis, cell
cycle regulation, checkpoints and DNA repair might affect cell sensitivity to the cytotoxic
effects of irinotecan [16,17]. Elevated expression of PARP1, TDP1 and XRCC1 are reported
to abate the cytotoxic action of camptothecins in yeast and mammalian cancer cells [18-21].
Genetic variation in TOP1 and the cellular downstream effectors that lead to DNA repair or
cell death are potential sources of patient-to-patient variation in irinotecan-induced toxicity
and clinical response [22]. This variation might allow improved prediction of patient outcomes
in response to irinotecan-based therapies.
Hoskins et al. previously tested the hypothesis that genetic variation in the pharmacodynamic
genes, including TOP1, PARP1, TDP1, XRCC1, CDC45L and NFKB1, influence patient
outcomes to irinotecan therapy in an exploratory study that utilized a haplotype-based study
approach [23]. In the study they assessed the relationships between genetic variability in the
pharmacodynamic genes and irinotecan treatment outcomes in a cohort of 107 white advanced
colorectal cancer patients treated with a median irinotecan dose of 180 mg/m2 (range: 80-350
mg/m2), administered as a single-agent or in combination with 5-fluorouracil or raltitrexed
[23]. By univariate analyses, genetic variation in TOP1 and PARP1 was associated with grade
III/IV neutropenia while variation in XRCC1 and TDP1 was associated with clinical response
in this cohort [23]
The goal of the present study was to evaluate the previous associations between TOP1, PARP1,
TDP1 and XRCC1 and irinotecan-related toxicity of neutropenia using an independent sample
of 85 cancer patients treated with single-agent 300-350 mg/m2 irinotecan using a haplotype
marker (htSNP) approach [23]. The influence of UGT1A1*28 on neutropenia has previously
been investigated in this patient cohort [10,13] and was also included in the analysis.
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A total of 85 patients with solid tumors or lymphoma of a type known to respond to irinotecan,
or for which no proven therapy of benefit exists, received 90 min intravenous infusions of 300
mg/m2 (n = 20) or 350 mg/m2 irinotecan (n = 65) once every 21 days (National Cancer Institute
[MD, USA] protocol #T98-0039, University of Chicago [IL, USA] protocol #9531) [10,13].
Patients gave written informed consent prior to being enrolled in the study. The present study
was approved by Washington University Medical Center Human Studies Committee,
Washington University School of Medicine, (MO, USA) (#05-1152) and The University of
Chicago Institutional Review Board (#05-125). The initial objectives of the studies were to
evaluate the influence of UGT1A1*28 genotype on irinotecan-related toxicities and the findings
were published else-where [10,13]. Patient pathological characteristics are outlined in Table
1.
DNA was collected for genetic analysis from all 85 patients. Absolute neutrophil counts
(ANCs) were collected weekly. Presence and grade of neutropenia and diarrhea were recorded
for all patients in accordance with the criteria of WHO. In the total cohort of 85 patients, 5
patients (6%) experienced grade III/IV diarrhea and 12 (14%) grade III/IV neutropenia.
Genotyping
Germline DNA samples from 85 patients were genotyped for six htSNPs (one insertion/
deletion and five SNPs) across TOP1, PARP1, TDP1 and XRCC1 (see Table 2 for a list of
polymorphisms). htSNPs were chosen as previously described from haplotype networks and
distinguished between three major haplotypes in a European sample [23]. Genotyping was
performed using PCR and Pyrosequencing® on the PyroMark MD (Qiagen, Hilden, Germany)
as previously described [23].
Statistics
Polymorphism and Haplotype Analysis Suite (PHASE version 0.9) was used to estimate pair
wise linkage disequilibrium (Dʑ) and haplotype identities and to assign diplotypes for
PARP1 and XRCC1 [24]. The prevalence of diarrhea was too low to permit statistical analysis
of this outcome. Our analyses concerned ANC and related grade III/IV neutropenia data
collected during the first cycle of chemotherapy and were performed for the total cohort and
European-American patients alone. Linear regression with the log(ANC nadir) as the outcome
variable was used to test associations between htSNP genotypes and diplotypes and irinotecan-
induced hematological toxicity. Analyses were adjusted for irinotecan dose (300 vs 350 mg/
m2), sex, ethnicity (European-American vs African-American), age and baseline ANC,
regardless of statistical significance. Grade III/IV neutropenia was compared between
genotype and diplotype groups using the χ2 test. We constructed a model to fit with an
interaction term to assess whether TOP1, PARP1, TDP1 and XRCC1 htSNPs and haplotypes
modulate the association between UGT1A1*28 genotype and ANC. A p-value of 0.05 was set
for statistical significance. No p-value adjustments were made for multiple comparisons. The
population size was limited by the availability of samples and data. In a post hoc calculation
of power, based on the known sample size (81 patients), number of grade III/IV neutropenia
events (12 patients), a two-sided type I error of 5%, and assuming a minor allele frequency of
20%, we had 80% power to detect an odds ratio of 7.2 or greater using the Fisher’s exact test
(two-by-two table) and an odds ratio of 5.9 using an uncorrected χ2 test (two-by-two table).
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TOP1, PARP1, TDP1 & XRCC1 genotypes
Patient DNA samples were typed for six htSNPs across the candidate genes. Allele and
genotype frequencies of the six htSNPs are presented in Table 2. For the patients of European
descent (which is the majority of patients, n = 67), all observed genotype frequencies were in
agreement with the Hardy-Weinberg equation (p > 0.05).
PARP1 & XRCC1 haplotype identities
Haplotypes were estimated for PARP1 and XRCC1. For each gene, some individuals were
homozygous at both loci and others heterozygous at one locus, which provided unambiguous
information about the specific combinations of alleles. For both genes, some individuals were
homozygous for all loci and others were heterozygous at a single site, which provided
unambiguous information about the specific combinations of alleles. Other diplotypes were
inferred by PHASE. The estimated haplotypes for PARP1 were T-C, C-C and T-T from c.
852T>C and IVS19-297C>T with frequencies of 0.42, 0.38 and 0.19, respectively. For
XRCC1, del-G (frequency = 0.42), GGCC-A (0.26) and GGCC-G (0.32) were estimated from
alleles -1449delGGCC and c.1196G>A. The numbers of patients with (and frequencies of)
each diplotype are presented in Tables 3 & 4.
Associations between irinotecan-induced hematological toxicities & pharmacodynamic
genes
TOP1, PARP1, TDP1 and XRCC1 htSNPs were not associated with first-cycle log(ANC nadir)
in the total cohort (Figure 1A & 1B) nor in the European-American patients analyzed alone.
In addition, PARP1 and XRCC1 haplotypes (Figure 1C) were not associated with first-cycle
log(ANC nadir). Moreover, genotypes and diplotypes were not associated with the incidence
of first-cycle grade III/IV neutropenia in the total cohort or European-American patients tested
alone (p > 0.30).
Gene-gene interactions between pharmacodynamic genes & UGT1A1*28 UGT1A1*28
genotype was associated with first-cycle log(ANC nadir), with a significant trend towards
lower ANC nadir from *1/*1 to *1/*28 to *28/*28 (p > 0.0001), as previously reported [10,
13]. Patients homozygous for UGT1A1*28 and XRCC1 -1449 GGCC had significantly lower
nadirs than the other patients (p = 0.002, test for interaction) (Figure 2). We did not find
significant interactions between UGT1A1*28/*28 and the other genotypes with respect to first-
cycle ANCs in the total cohort and European-American patients alone (p > 0.1).
Discussion
Camptothecins, including SN-38, exert their cytotoxic effects by reversibly stabilizing the topo
I-DNA covalent complex, trapping the complex and preventing religation of nicked DNA. The
camptothecin-topo I-DNA complex collides with advancing replicating forks, which convert
the single-strand DNA breaks to double-strand breaks that can not be easily resealed. This
induces irreversible arrest of the replication fork and may lead to cell death. Genetic variation
in the drug target of SN-38, TOP1 and cellular downstream effectors that lead to DNA repair
or cell death might be sources of patient-to-patient variation in irinotecan-induced toxicity and
clinical response [22]. In the present study, we investigated whether genetic variation in
TOP1, and genes encoding other camptothecin pharmacodynamic factors, including PARP1,
TDP1 and XRCC1, influences first-cycle ANC nadirs and related first-cycle grade III/IV
neutropenia in 85 cancer patients with solid tumors or lymphoma treated with moderately high-
dose, single-agent irinotecan (300 or 350 mg/m2 every 21 days). Although a previous study
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showed that genotypes and diplotypes of TOP1, PARP1, TDP1 and XRCC1 influenced
outcomes to irinotecan-based therapies [23], these results could not be replicated in an
independent cohort. Our analysis suggests genetic variation in TOP1, PARP1, TDP1 and
XRCC1 does not explain severe neutropenia in this irinotecan treated cohort.
It is plausible that associations between polymorphisms in pharmacodynamic genes and
toxicity are irinotecan dose-dependent, such that differences in irinotecan doses that were
administered among the studies explains the inconsistent genetic associations [23]. In the
present study, patients received moderately high doses of irinotecan (300 or 350 mg/m2, every
21 days) and UGT1A1*28/*28 genotype was significantly associated with grade III/IV neutro
penia (seven of 12 UGT1A1*28/*28 patients experienced neutropenia [58%], p = 0.0002)
[10,13]. In the previous study, where patients were treated with irinotecan monotherapy or in
combination with 5-fluorouracil or raltitrexed at a median dose of 180 mg/m2 irinotecan every
14 days, with doses ranging from 80-350 mg/m2 irinotecan (administered every 7, 14 or 21
days), UGT1A1*28 genotype was not associated with grade III/IV neutropenia (p = 0.5) [23].
These genotype-toxicity associations are consistent with the findings of a recent meta-analysis
of 821 cancer patients treated with irinotecan [15]. Specifically, a large effect size (odds ratio
[OR]: 27.8; p = 0.005) for the association of the UGT1A1*28/*28 genotype with neutropenia
was observed at higher doses of irinotecan (>250 mg/m2), a moderate effect size (OR: 3.2; p
= 0.008) at medium doses (150-250 mg/m2), and a weak, nonsignificant effect size (OR: 1.8;
p = 0.41) at lower doses of irinotecan (<150 mg/m2) [15]. These findings suggest
UGT1A1*28/*28 genotype is a good determinant of risk of neutropenia when patients receive
higher doses of irinotecan but is not predictive when they receive lower doses (<150 mg/m2).
The larger effect size of the UGT1A1*28 on irinotecan-related neutro penia at higher irinotecan
doses may have overshadowed the smaller effect sizes of the pharmacodynamic gene variants
on neutropenia, thereby reducing the power of the present study to detect the latter genetic
associations.
The present study was undertaken to replicate the findings of Hoskins et al. [23]. In that study,
patients of European ancestry were genotyped for htSNPs that distinguished between major
haplotypes in a European-American sample. The htSNPs are not considered functional or
known to be in strong linkage with alleles of known functional importance [23]. In the present
study we evaluated whether the same set of htSNPs were associated with irinotecan-related
neutropenia in an independent cohort of patients. Some polymorphisms in the
pharmacodynamic genes have been shown to alter the function of these proteins in vitro and
to be risk factors for various cancers [25-28]. However, patients in the present study were not
genotyped for these functional variants because they were not associated with outcomes to
irinotecan therapy in a prior study [23]. The present cohort was of mixed ethnicity, with the
majority of patients being European-American (79%). The distribution of haplotypes for the
pharmacodynamic genes varies among ethnic groups [23] and so too might the degree of
linkage disequilibrium between htSNPs and irinotecan response altering alleles in the genes
[23]. This may have limited our power to detect associations in the present study. However,
associations between the htSNPs and irinotecan-related neutropenia were not observed for the
European-American patients when analyzed alone suggesting that this does not explain the
inconsistent genetic associations among the studies [23].
We may not have detected any associations between pharmacodynamic genes and neutrophil
nadir in the present study because there were none to find (i.e., true negatives). There may be
additional variants that were not evaluated in this study. Certainly other genes may also
contribute to variation in irinotecan effect. Alternatively, the observations of the earlier
exploratory study may have been false positives due to limitations in sample size [23]. Genetic
variations in TOP1 and PARP1 were found to predict grade III/IV neutropenia by univariate
statistical tests but not by multiple logistic regression, suggesting the associations detected by
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univariate analyses may have been false positives [23]. However, it is possible the associations
detected in the earlier study by univariate analyses were true positives but the study may have
lacked adequate power to detect these associations by multivariate analysis because the
numbers of homozygous variants were low and the size of effects were small-to-moderate and
the study was powered to detect large effect sizes.
Patients homozygous for UGT1A1*28 and XRCC1 -1449 GGCC appeared to have lower first-
cycle ANC nadirs than the other patients (p < 0.0001). However, the limited sample size, the
small number of individuals with the combined genotype (n = 5), the lack of influence of the
XRCC1 insertion/deletion on first-cycle ANCs (by univariate statistical test), and that the
relationship between XRCC1 -1449 genotypes and ANCs for patients with the UGT1A1*1/
*1 and *1/*28 genotypes appears to be in the opposite direction, suggest that this may not be
a true association and caution should be exercised when interpreting this gene-gene interaction
observation.
Conclusion
In conclusion, the present study represents an attempt to confirm observations from a previous
pharmacogenetic study in which Hoskins et al. demonstrated germline variations in genes that
play a role in camptothecin pharmacodynamics influenced outcomes to irinotecan-based
therapies in a separate patient population [23]. Using a sample of cancer patients treated with
moderately high-dose single-agent irinotecan, we failed to confirm the findings of the initial
study suggesting that in the case of moderately high-dose irinotecan, TOP1, PARP1, TDP1
and XRCC1 play minor or negligible roles in patient-to-patient variation in irinotecan treatment
outcomes.
Executive summary
■ Patients with the UGT1A1*28/*28 genotype have reduced detoxification of the
active metabolite of irinotecan, SN-38 and an elevated risk of severe irinotecan-
related neutropenia. However this genetic variant does not explain all of the
patient-to-patient variation in irinotecan-related toxicity or efficacy.
■ A recent study found that variation in camptothecin pharmacodynamic genes,
TOP1, PARP1, TDP1 and XRCC1, correlated with efficacy and risk of neutropenia
in irinotecan-treated cancer patients (median dose: 180 mg/m2).
■ These genetic variants may influence outcomes to irinotecan-based therapies.
Materials & methods
■ A total of five SNPs and an insertion/deletion polymorphism across TOP1, PARP1,
TDP1 and XRCC1 were determined in a total of 85 patients with cancer treated
with moderately high-dose single-agent irinotecan (300 or 350 mg/m2) as part of
a Phase I trial.
■ Genotyping was performed using PCR and Pyrosequencing® on the PyroMark
MD (Qiagen, Hilden, Germany).
Results
■ TOP1, PARP1, TDP1 and XRCC1 genotypes, and PARP1 and XRCC1 diplotypes
were not associated with first-cycle log(absolute neutrophil counts nadir) or
incidence of first-cycle grade III/IV neutropenia in the total cohort and the
European-Americans analyzed alone.
Hoskins et al. Page 6













■ Patients homozygous for UGT1A1*28 and XRCC1 -1449 GGCC had significantly
lower nadirs than the other patients (p = 0.002, test for interaction). Gene-gene
interactions between UGT1A1*28/*28 and the other pharmacodynamic variants
with respect to first-cycle ANCs or grade III/IV neutropenia were not observed.
Discussion
■ TOP1, PARP1, TDP1 and XRCC1 do not appear to be influencing factors of
response to moderately high-dose single-agent irinotecan therapy in cancer
patients.
■ In addition to UGT1A1*28, factors (genetic or nongenetic) other than the genetic
variants studied in the current study may be determinants of response to irinotecan
at higher doses of irinotecan.
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Relationships between first-cycle log(ANC nadir) and (A) XRCC1 -1449delGGCC and (B)
XRCC1 c.1196 genotypes and (C) XRCC1 (-1449delGGCC-c.1196) diplotypes (p > 0.10).
ANC: Absolute netrophil count.
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Interactions between UGT1A1*28 and XRCC1 -1449delGGCC genotypes and first-cycle log
(ANC nadir) (p < 0.0001). ANC: Absolute netrophil count.
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